Citidaron FAQ

Yes, cytisine and cytisinicline are the same. Although the generic name (INN) Cytisine has been widely used for many decades, more recently the WHO proposed changing this to cytisinicline. You may therefore find it listed under “cytisine”, “cytisinicline”, or both.

Citidaron is supplied with 2 foil strips of 50 tablets; 100 tablets is enough for a complete 25-day course. There are no dosing instructions printed on the foil strips; however, each pack is provided with a Patient Information Leaflet detailing how to take the medication.

Also, Consilient Health has created a supplementary Patient Leaflet & Dosing Guide. This includes a chart that allows patients to mark-off when they have taken each dose throughout the full 25-day treatment course. These can be supplied by Consilient Health (contact us here to request copies or to download as a pdf from our website.)

Due to limited clinical experience based on the clinical trial data available at the time Citidaron was licensed, the safety and efficacy of Citidaron in these age groups has not been established and is therefore not recommended.

The SPC states that, due to lack of clinical experience, Citidaron is not recommended in patients with renal or hepatic impairment. As the SPC does not specify a particular level of hepatic or renal impairment, this implies any impairment.

The Citidaron SPC contraindicates use in patients with a history of “recent myocardial infarction” or “recent stroke”. However, “recent” is not defined in the SPC as the information was not collected during the original clinical trials, so a specific time period cannot be advised.

The use of Citidaron is a clinical decision for the prescriber who is familiar with the patient’s underlying condition. Citidaron can be used in patients with certain cardiovascular conditions, i.e. “ischemic heart disease, heart failure, hypertension, pheochromocytoma, atherosclerosis and other peripheral vascular diseases”, however, the SPC states that it should be used with caution.

The Patient Information Leaflet (PIL) advises that patients should “not take a double dose to make up for a forgotten dose”. A PIL is provided, in each pack of Citidaron.